Malaria

Dr Simon Cobbold, Dr Tuo Yang and Prof Leann Tilley, celebrating their discovery of the mechanism of artemisinin resistance, published in Cell Reports today.

Professor Leann Tilley and Dr Stanley Xie from the Bio21 Institute are working with experts from the Japanese company, Takeda Pharmaceuticals, and Swiss-based foundation, Medicines for Malaria Venture (MMV), in a double-pronged effort to develop new antimalarial drugs.  

Capitalising on the revolution brought about by structural cryo-electron microscopy (cryo-EM), a Bio21 team led by Dr Mike Griffin and Prof Leann Tilley has generated molecular movies of a sophisticated nano-machine, called the proteasome. 

Collective intelligence needed to solve malaria. Hear Leann Tilley explain

Scientists have made a major breakthrough in the global search for a new drug to beat the malaria parasite’s growing resistance to first-defence treatments.

Professor Leann Tilley and Stanley Cheng Xie from the Bio21 Institute are joining with Takeda Pharmaceuticals in the fight against malarial drug resistance.